Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T52389
|
||||
Former ID |
TTDC00200
|
||||
Target Name |
NAD(P)H dehydrogenase [quinone] 1
|
||||
Gene Name |
NQO1
|
||||
Synonyms |
Azoreductase; DT-diaphorase; DT-diaphorase 1; DTD; Menadione reductase; NAD(P)H:quinone oxidoreductase 1; Phylloqui reductase; Phylloquinone reductase; QR1; Qui reductase 1; Quinone reductase 1; NQO1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Huntington's disease [ICD9: 294.1, 333.4; ICD10: F02.2, G10] | ||||
Function |
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
|
||||
BioChemical Class |
Oxidoreductases acting on NADH or NADPH
|
||||
Target Validation |
T52389
|
||||
UniProt ID | |||||
EC Number |
EC 1.6.5.2
|
||||
Sequence |
MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKL
KDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERV FIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFC GFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMK KEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK |
||||
Drugs and Mode of Action | |||||
Inhibitor | 2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one | Drug Info | [530490] | ||
3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one | Drug Info | [530490] | |||
3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one | Drug Info | [530490] | |||
3-Benzyl-4-hydroxy-2H-chromen-2-one | Drug Info | [530490] | |||
3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one | Drug Info | [530490] | |||
4-amino-2H-chromen-2-one | Drug Info | [529150] | |||
4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one | Drug Info | [530490] | |||
4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one | Drug Info | [530490] | |||
Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone] | Drug Info | [551393] | |||
Duroquinone | Drug Info | [551393] | |||
ES-936 | Drug Info | [529109] | |||
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate | Drug Info | [530490] | |||
Flavin-Adenine Dinucleotide | Drug Info | [551393] | |||
NSC-106080 | Drug Info | [531262] | |||
NSC-106547 | Drug Info | [528457] | |||
NSC-2113 | Drug Info | [528457] | |||
NSC-224124 | Drug Info | [528457] | |||
NSC-275420 | Drug Info | [528457] | |||
NSC-316158 | Drug Info | [528457] | |||
NSC-339580 | Drug Info | [528457] | |||
NSC-339583 | Drug Info | [528457] | |||
NSC-354279 | Drug Info | [528457] | |||
NSC-621351 | Drug Info | [531262] | |||
NSC-645808 | Drug Info | [528457] | |||
NSC-645827 | Drug Info | [528457] | |||
NSC-65069 | Drug Info | [531262] | |||
NSC-73410 | Drug Info | [528457] | |||
NSC-99528 | Drug Info | [531262] | |||
Quinones | Drug Info | [535275] | |||
Modulator | Coenzyme Q10 analog | Drug Info | [544447] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Ubiquinone and other terpenoid-quinone biosynthesis | ||||
NetPath Pathway | TCR Signaling Pathway | ||||
Pathway Interaction Database | Validated transcriptional targets of TAp63 isoforms | ||||
PathWhiz Pathway | Vitamin K Metabolism | ||||
WikiPathways | Estrogen metabolism | ||||
Oxidative Stress | |||||
Transcriptional activation by NRF2 | |||||
NRF2 pathway | |||||
Nuclear Receptors Meta-Pathway | |||||
Aryl Hydrocarbon Receptor Pathway | |||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
Metabolism of amino acids and derivatives | |||||
Aryl Hydrocarbon Receptor | |||||
Dopamine metabolism | |||||
Arylhydrocarbon receptor (AhR) signaling pathway | |||||
References | |||||
Ref 528457 | Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. Epub 2006 Sep 29.In silico identification and biochemical characterization of novel inhibitors of NQO1. | ||||
Ref 529109 | J Med Chem. 2007 Nov 15;50(23):5780-9. Epub 2007 Oct 18.Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. | ||||
Ref 529150 | J Med Chem. 2007 Dec 13;50(25):6316-25. Epub 2007 Nov 14.Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. | ||||
Ref 530490 | J Med Chem. 2009 Nov 26;52(22):7142-56.Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). | ||||
Ref 531262 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). | ||||
Ref 535275 | Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. Structure. 2001 Aug;9(8):659-67. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.